Robert Newman

Partner

Emailrobert.newman@dlapiper.com

Call+44 (0)333 207 7814

Birmingham

About

Areas of FocusLife Sciences Corporate

Professional QualificationsSolicitor of the Senior Courts of England and Wales

EXPERIENCE

Acting for Benjamin Moore (a Berkshire Hathaway portfolio company) on two UK business acquisitions in the manufacturing sector
Acting for AIM listed Thalia Therapeutics on its acquisition of Sanmirna Therapeutics and associated follow-on fundraise
Acting for Hayley Dexis on the acquisition of Digital Industrial Radiography Systems Ltd operating in the defense, aerospace and manufacturing sector
Acting for Dechra Pharmaceuticals on its class one acquisition of AST Pharma and Le Vet and associated accelerated bookbuild placing
Acting for Iron Mountain on its disposal of its paper shredding businesses in UK, Australia and Ireland to Shred-lt.
Acting for ARM on its acquisition of NextG-Com.
Acting for Lotus Bakeries on its acquisition of Urban Fresh Foods.
Acting for Kelda (Yorkshire Water) on its disposal of two major infrastructure assets to Ancala.
Acting for AirHop on multiple trampoline park acquisitions.
Acting for Dechra Pharmaceuticals on its GBP4.5 billion take private by EQT
Acting for Medica Group on its GBP269 million take private by IK Partners.
Acting Synergy Health on STERIS Corporation's USD5.2 billion takeover (tax inversion).
Acting Clinigen on its GBP150 million public takeover of Quantum Pharma.
Acting for Watkin Jones on its GBP255 million AIM IPO.
Acting for Knights on its GBP103.5 million AIM IPO.
Acting for Liberum Capital as Nomad and bookrunner on Time Out’s GBP195 AIM IPO.
Acting for Numis (sponsor and joint bookrunner) and Shore Capital (joint bookrunner) on the GBP200 million IPO of Motorpoint on to the Main Market.
Acting for numerous issuers and banks/underwrites on various follow-on offerings (rights issues, open offers, placings etc), returns of capital (tender offers), block trades etc
Acting for The Gap, Inc. in establishing its joint venture with Next to ensure its products continue to be sold in the UK and Irish markets
Acting for National Grid in establishing a joint venture partnership with a major UK housebuilder in respect of developing out its land bank.
Acting for the Welsh Government in establishing a joint venture in respect of a major infrastructure project.
Acting for ASX listed Starpharma on its strategic partnership with life sciences investment firm Medicxi
Acting for Baker Hughes and Hyundai in their investment in Elcogen Group

DIRECTORIES

Rob is ranked as an “Up and Coming” partner in Chambers & Partners and "Next generation partner" in Legal 500 (both in terms of Corporate M&A and Equity Capital Markets.

"Robert Newman…with a burgeoning corporate practice… is particularly adept at assisting clients with acquisitions and investments, with a particular focus on the life sciences sector." Chambers & Partners 2026

"Rob Newman is a really diligent and earnest lawyer - he has good client relationships and is a real deal maker." Chambers & Partners 2023

Education

University of Law, GDL & LPC

University of Leicester, BA Politics

Publications

Thinking of listing in London: which market is right for you?, 26 March 2026
UK pharma gets a festive boost with US tariff-free deal, 3 December 2025
Potential US rule changes could result in more London listings, 14 July 2025
Britain fast-tracks biggest company listings shake-up in decades (Reuters), 11 July 2024

Memberships And Affiliations

Rob is an honorary lecturer at the University of Cambridge and the University of Birmingham.
Rob is a member of the London Stock Exchange’s Regional Advisory Group.